Table 4.
Outcome of Respiratory Syncytial Virus and Cytomegalovirus Pneumonia in Adult Bone Marrow Transplant Recipients
| Mortality (%) |
||
|---|---|---|
| Therapya | RSV (n = 23)b | CMV (n = 29)c |
| Earlyd | 4/13 (31) | 7/12 (58) |
| Early (6 h/day) | 1/1 (100) | — |
| Lated | 5/5 (100) | 11/11 (100) |
| None | 4/4 (100) | 5/6 (83) |
| Overall | 14/23 (61) | 23/29 (79) |
RSV = respiratory syncytial virus; CMV = cytomegalovirus.
Therapy for CMV pneumonia consisted of ganciclovir (or occasionally foscarnet) and intravenous immunoglobulin (IV Ig; 500 mg/kg every other day). Therapy for RSV pneumonia consisted of aerosolized ribavirin (20 mg/mL for 18 h/day) and IV Ig (500 mg/kg every other day). One patient received aerosolized ribavirin (60 mg/mL for 2 h every 8 h) and IV Ig.
23 consecutive cases of RSV pneumonia occurring in adult bone marrow transplant (BMT) recipients hospitalized at M. D. Anderson Cancer Center (MDACC) from November 1992 to November 1995.
29 consecutive cases of CMV pneumonia occurring in allogeneic BMT recipients hospitalized at MDACC during 1991–1994.
Therapy was classified as “early” or “late” depending on whether it was initiated >24 h or <24 h prior to respiratory failure requiring mechanical ventilation, respectively.